Gene targeting comes to top-down drug screens

With very few exceptions, cancer drug screening has been stuck with the multiple variable approach. While those of us working with model genetic systems would regard with horror experiments using non-isogenic strains or outbred lines, cells that differ from common human tumor cells by simple and/or defined genetic traits are generally not available. A recent paper published by Torrance et al. takes an important step towards a more rational and controlled approach in the area of cancer drug screening.